Genkyotex is a leader in NOX therapies, with a unique therapeutic approach based on the selective inhibition of NOX enzymes. The NOX enzymes amplify multiple pathways involved in disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

Genkyotex’s platform allows identification of orally available smallmolecules which selectively inhibit specific NOX enzymes. Genkyotex develops a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes.

The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is expected to enter a phase II clinical trial in primary biliary cholangitis (PBC, an orphan fibrotic disease). This product candidate may also be active in additional fibrotic indications.

Its second product candidate, GKT771, is a NOX1 inhibitor targeting multiple pathways in angiogenesis, pain processing, and inflammation.